Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes

(2012) M. C. Thomas et al.   PPAR Research

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

(2011) Barbara C Hansen et al.   Cardiovascular Diabetology

How Useful is Basal Renal Tubular Epithelial Cell Vacuolization as a Marker for Significant Hyperglycemia at Autopsy?

(2011) Chong Zhou et al.   JOURNAL OF FORENSIC SCIENCES

Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis

(2011) Inga Sörensen et al.   KIDNEY INTERNATIONAL

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

(2010) T. M. E. Davis et al.   DIABETOLOGIA

Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy

(2010) Lingyun Li et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

(2010) Matthias Herz et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Antifibrotic Effects of Pioglitazone at Low Doses on the Diabetic Rat Kidney Are Associated with the Improvement of Markers of Cell Turnover, Tubular and Endothelial Integrity, and Angiogenesis

(2010) Jorge E. Toblli et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

(2009) Agnes Bénardeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Fibrate therapy and renal function

(2009) Domenic A. Sica   Current Atherosclerosis Reports

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus

(2009) J. E. Toblli et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Tesaglitazar, a Dual Peroxisome Proliferator- Activated Receptor Agonist (PPARα/γ), Improves Metabolic Abnormalities and Reduces Renal Injury in Obese Zucker Rats

(2009) Jie Liao et al.   NEPHRON EXPERIMENTAL NEPHROLOGY

PPAR-Alpha Agonist Fenofibrate Induces Renal CYP Enzymes and Reduces Blood Pressure and Glomerular Hypertrophy in Zucker Diabetic Fatty Rats

(2008) Xueying Zhao et al.   AMERICAN JOURNAL OF NEPHROLOGY

Distal Degenerative Sensory Neuropathy in a Long-Term Type 2 Diabetes Rat Model

(2008) V. Brussee et al.   DIABETES

Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association

(2008) J. S. Skyler et al.   DIABETES CARE

Fibrates and future PPARα agonists in the treatment of cardiovascular disease

(2008) Bart Staels et al.   Nature clinical practice. Cardiovascular medicine

Effect of chronic rosiglitazone, metformin and glyburide treatment on β-cell mass, function and insulin sensitivity in mZDF rats

(2007) L. L. Atkinson et al.   DIABETES OBESITY & METABOLISM